Lion Works Digital Launches New HIPAA-Compliant Marketing Package for Addiction Treatment Centers
Lion Works Digital, a Nashville-based healthcare marketing agency, has expanded its specialized services to addiction treatment centers in Los Angeles, California, with the launch of a comprehensive HIPAA-compliant marketing package. This new offering addresses the unique challenges faced by drug and alcohol addiction treatment facilities in the competitive Los Angeles market while ensuring strict adherence to healthcare privacy regulations.
The specialized marketing package combines targeted digital strategies with healthcare compliance expertise to help addiction treatment centers increase their visibility and connect with individuals seeking recovery services. Chase Brantley, founder of Lion Works Digital, brings his proven track record of boosting client website traffic by over 300% to the addiction treatment sector in Los Angeles.
"Addiction treatment centers face unique marketing challenges that require specialized knowledge of both healthcare regulations and effective digital strategies," said Chase Brantley, healthcare marketing expert and founder of Lion Works Digital. "Our new HIPAA-compliant marketing package helps Los Angeles addiction treatment centers reach those in need while maintaining the highest standards of privacy and compliance."
The comprehensive marketing solution addresses the specific needs of drug and alcohol rehab centers in Los Angeles by implementing data-driven strategies tailored to the addiction treatment industry. These strategies include specialized SEO techniques for rehab centers, HIPAA-compliant content marketing, and targeted digital advertising campaigns designed to connect with individuals seeking addiction treatment services.
With the expansion into the Los Angeles market, Lion Works Digital brings its expertise in drug rehab marketing strategies to one of the nation's largest centers for addiction treatment. The agency's approach focuses on ethical promotion practices that prioritize transparency and patient well-being while helping treatment facilities stand out in a competitive landscape.
The HIPAA-compliant marketing package includes comprehensive SEO optimization specifically designed for rehab centers in Los Angeles. This strategy enhances online visibility for local searches, helping treatment centers appear prominently in "near me" searches and Google Maps results. By focusing on location-specific keywords and building local citations, Lion Works Digital helps addiction treatment centers connect with individuals seeking recovery services in their area.
Content marketing for substance abuse recovery forms another crucial component of the package. The agency creates valuable, informative content that addresses the needs and concerns of individuals seeking addiction treatment in Los Angeles. This approach not only improves search rankings but also establishes treatment centers as trusted resources for those seeking information about recovery options.
For luxury drug and alcohol rehab centers in Los Angeles, the marketing package includes specialized strategies designed to highlight premium amenities and exclusive treatment approaches. This targeted marketing helps luxury facilities reach high-value clients seeking premium addiction treatment services.
Lion Works Digital's expertise in drug rehab SEO marketing helps treatment centers improve their visibility for relevant search terms, driving targeted traffic to their websites. The agency's data-driven approach ensures that marketing efforts focus on keywords and strategies that deliver measurable results.
The agency's experience with rehabilitation facility marketing helps treatment centers in Los Angeles effectively communicate their unique treatment approaches, facility amenities, and program benefits. This targeted messaging helps potential clients understand what makes each treatment center unique and how it can address their specific needs.
For sober living homes in Los Angeles, the marketing package includes specialized strategies designed to highlight the supportive environment and recovery resources available. This targeted approach helps sober living facilities connect with individuals transitioning from intensive treatment to independent living.
About Lion Works Digital:
Lion Works Digital is a Nashville-based healthcare marketing agency specializing in data-driven, customized digital marketing solutions for healthcare providers and practices. Founded by Chase Brantley, a healthcare marketing expert with a proven track record of boosting clients' website visitors by over 300%, Lion Works Digital leverages data and automation to craft winning digital strategies. The agency focuses on helping small to medium-sized healthcare companies improve their online presence through services including SEO, PPC advertising, social media marketing, and website design. Lion Works Digital is committed to delivering measurable results for clients while maintaining the highest standards of healthcare compliance.
For more information, please contact Chase Brantley at https://lionworksdigital.com/
Media Contact
Company Name: Lion Works Digital LLC
Contact Person: Chase Brantley
Email: Send Email
Phone: +16156010394
Address: 2942 Burtonwood Drive
City: Spring Hill
State: TN
Country: United States
Website: https://lionworksdigital.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
16 minutes ago
- Globe and Mail
Wellness Eternal Releases July 2025 Biohacking Index Report: Verified Top-Rated Companies Leading the Future of Wellness
Wellness Eternal Launches First-Ever Biohacking Index Report Monthly rankings establish third-party verification standard for wellness industry Valhalla, New York--(Newsfile Corp. - August 20, 2025) - Wellness Eternal today announced the release of the July 2025 Biohacking Index Report, the first in a monthly series ranking wellness and longevity companies based on verified reviews from doctors, clinic owners, health professionals, customers, and patients. The July 2025 Biohacking Index highlights a fiercely competitive field with multiple companies securing perfect 5.0 ratings, showcasing the rising standards and excellence in the biohacking industry. To view an enhanced version of this graphic, please visit: The Biohacking Index is a third-party verified platform that evaluates companies based on verified reviews from healthcare professionals and customers. Only Premium Members are eligible to be officially indexed and included in the monthly reports. July 2025 Report Results The July 2025 report features eleven companies with ratings between 4.8 and 5.0, with eight receiving perfect 5.0 scores based on verified reviews from healthcare professionals and customers. The companies achieving perfect 5.0 scores include companies across diverse segments from diagnostics to therapeutic devices. The full report, available at includes detailed company profiles, locations, ratings, and review sources. "This is more than a ranking-it's a verified record of what's actually working in the wellness world," said Lindsay O'Neill, founder of Wellness Eternal and the Biohacking Index. "By combining verified consumer feedback with practitioner input, we're establishing a verification standard for transparency in biohacking." The timing of this launch reflects growth in the wellness industry, with biohacking representing an expanding market segment. Expanding Industry Impact and Future Focus As a contributor to established media publications, O'Neill distributes data from the Biohacking Index Monthly Report to over 300 news media outlets, as well as directly to investors, wellness buyers, and practitioners seeking reliable market intelligence. Starting in August 2025, each report will focus on a specific category, beginning with Red Light Therapy, followed by PEMF & Vibration, HBOT (Hyperbaric Oxygen Therapy), Detox & Lymphatic Health, and Diagnostics. This category-specific approach will provide deeper market insights and help establish performance benchmarks within specialized wellness sectors. About Wellness Eternal and the Biohacking Index Founded by biohacking expert Lindsay O'Neill, Wellness Eternal is dedicated to advancing transparency and accountability in the wellness industry. The Biohacking Index is a ratings and reviews platform for biohacking, longevity, and wellness companies. The platform provides information to help consumers and practitioners make informed decisions.
Globe and Mail
16 minutes ago
- Globe and Mail
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ('Vivani' or the 'Company'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Wednesday, September 10, 2025 Time: 1:00 PM - 1:30 pm, Eastern Time Location: Lotte New York Palace Hotel, Holmes I - 4th Floor Dr. Mendelsohn will highlight Vivani's portfolio of miniature, ultra long-acting drug implants, powered by its proprietary NanoPortal™ drug implant technology. These innovative implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. The Company is prioritizing the advancement of NPM-139, a novel semaglutide implant, with clinical development expected to begin in 2026, pending regulatory clearance. More information about the H.C. Wainwright 27th Annual Global Investment Conference can be found at About Vivani Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Today, medication non-adherence affects approximately 50% of patients. Vivani's priority product candidate, NPM-139, is a miniature, six-month, subdermal, GLP-1 (semaglutide) implant under development for chronic weight management in obese or overweight subjects. NPM-139 has the added potential for once-yearly dosing. Vivani's emerging pipeline also includes NPM-115 (exenatide implant) for chronic weight management in obese and overweight individuals, and NPM-119, an exenatide implant program for the treatment of type-2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability and loss of efficacy. Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 Phase 1 study and reporting of study results, Vivani's emerging development plans for NPM-139, NPM-115, NPM-119 or Vivani's plans with respect its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-139, NPM-115, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities, including Vivani's ability to commence clinical development of NPM-139; risks related to the initiation, enrollment and conduct of Vivani's planned clinical studies and the results therefrom; or Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer info@ (415) 506-8462 Investor Relations Contact: Jami Taylor Investor Relations Advisor investors@ (415) 506-8462 Media Contact: Mark Corbae ICR Healthcare (203) 682-8288
Globe and Mail
16 minutes ago
- Globe and Mail
Real's July Agent Survey: Agent Optimism Index Jumps to Four-Month High as Transaction Activity Shows Signs of Improvement
The Real Brokerage Inc. (NASDAQ: REAX, 'Real'), a leading real estate technology platform redefining the industry through innovation and culture, today released results from its July 2025 Agent Survey. The data shows a significant rebound in agent optimism and an improving trend in home sales activity relative to June, despite ongoing affordability concerns, and a continued shift in negotiating leverage toward buyers. It also highlights the critical importance of service, communication, and responsiveness when agents advise clients on which mortgage and title service providers to work with. 'Our July survey confirms that the ongoing pressure from affordability and macroeconomic concerns is cementing a firm shift to a buyer's market across the industry,' said Tamir Poleg, Chairman and CEO of Real. 'The survey also shows that clients lean heavily on their agents for advice and guidance on which ancillary service providers to use, indicating that providers who deliver transparent communication and timely service stand out. We believe in the future, greater adoption of technology and AI can enhance service levels and better address this critical need for clients.' Key Survey Findings: Market Trends and Insights Agent Optimism Rebounds to Highest Level in Four Months: Real's Agent Optimism Index, which measures agents' 12-month outlook for their local markets, jumped significantly to 67.2 in July from 59.5 in June. This marks the highest reading in four months, with 63% of agents feeling more optimistic compared to the prior month, including 15% who felt significantly more optimistic. (Scores are weighted on a 0-100 point scale, with scores above 50 indicating net optimism and scores below 50 signaling net pessimism.) Transaction Activity Shows Gradual Improvement: Real's Transaction Growth Index, which tracks agent-reported year-over-year changes in home sales activity within their local markets, rose to 49.3 in July, an improvement from 46.2 in June. This suggests that the pace of decline in transaction activity was more moderate in July than in June. The data shows that while 37% of agents saw fewer transactions compared to last July, 34% saw an increase, and 29% reported activity that was approximately flat year-over-year. (Note: This index reflects agents' perceptions of local market trends and is not indicative of Real's company-specific transaction volume. Scores are weighted on a 0-100 point scale, with scores above 50 indicating year-over-year growth and scores below 50 signaling a decline.) Markets Continue to Favor Buyers: In July, 52% of agents said their local market favors buyers, up from 48% in June. Only 19% said it favored sellers, a notable drop from 26% in June, with 29% describing conditions as balanced. Affordability and Economic Uncertainty Remain Top Challenges: Affordability continues to be the top challenge for buyers, cited by 58% of agents in July, an increase from 51% in June. Economic uncertainty also remains a significant hurdle, cited by 22% of agents in July, down from 26% in June. Meanwhile, inventory constraints and buyer competition were seen as lesser issues, cited by 12% and 5% of agents, respectively. Key Survey Findings: Agents Role in Recommending Closing Services Providers The survey findings reveal that agents play a critical role in navigating clients throughout a real estate transaction, and their recommendations on mortgage and title service providers hold significant influence over a client's ultimate decision on which provider to choose. Clients Rely More on Agents for Title than Mortgage: A much higher rate of agents (62%) reported that their clients use their recommended title provider nearly always (75%-100% of the time), compared to just 40% who mentioned clients nearly always work with their recommended mortgage provider. This suggests clients are more willing to defer to their agent's judgment for title work, while they are more likely to shop for mortgage rates. Service Is Everything: Responsiveness and Communication are the Key: When asked to name the single most important factor in recommending a closing services provider, agents gave the following responses: For Mortgage Services: For Title Services: Responsiveness and communication of the title officer: 39.0% Accuracy and efficiency of title work: 29.8% Existing relationship with the provider: 16.1% Speed and certainty of title clearance and closing: 15.2% What Would Make an Agent Recommend a New Provider? The survey reveals that beyond pricing, the most compelling reasons that would prompt agents to switch closing services partners fall into four key buckets: Speed: Faster and more reliable closings are a primary motivator, cited by 29.9% of agents for mortgage providers and 25.7% for title providers. Dedicated Support: Having a dedicated support team with proactive communication specifically for that agent's brokerage is a major driver, selected by 25.9% of agents for mortgage and 26.3% for title. Technology: Superior, easy-to-use technology is also a significant factor for both, at 14.7% for mortgage and 17.8% for title. Seamless integration with brokerage platforms was a lesser but still present factor. Nothing: A notable percentage of agents said nothing currently listed would compel them to switch from their current provider, at 15.2% for mortgage and 18.6% for title. A full summary of these results can be found on Real's investor relations website at About the Survey The Real Brokerage July 2025 Agent Survey included responses from over 550 real estate agents across the United States and Canada and was conducted between July 31, 2025 and August 14, 2025. Responses to questions regarding transaction growth and agent optimism were calibrated on a 0-100 point index scale, with readings above 50 indicating an improving trend, whereas readings below 50 indicate a declining trend. Responses are meant to capture industry-level information and are not meant to serve as an indication of Real's company-specific growth trends. Additionally, given the smaller sample size, there can be greater variability in Canada index results on a month-to-month basis. About Real Real (NASDAQ: REAX) is a real estate experience company working to make life's most complex transaction simple. The fast-growing company combines essential real estate, mortgage and closing services with powerful technology to deliver a single seamless end-to-end consumer experience, guided by trusted agents. With a presence in all 50 states throughout the U.S. and Canada, Real supports over 29,000 agents who use its digital brokerage platform and tight-knit professional community to power their own forward-thinking businesses. Forward-Looking Information This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as 'seek', 'anticipate', 'believe', 'plan', 'estimate', 'expect', 'likely' and 'intend' and statements that an event or result 'may', 'will', 'should', 'could' or 'might' occur or be achieved and other similar expressions. These statements reflect management's current beliefs and are based on information currently available to management as of the date hereof. Forward-looking information in this press release includes, without limiting the foregoing, expectations regarding the residential real estate market in the U.S. and Canada. Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to expectations regarding 2025 market conditions. Real considers these assumptions to be reasonable in the circumstances. However, forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied in the forward-looking information. Important factors that could cause such differences include, but are not limited to, slowdowns in real estate markets and economic and industry downturns, and those risk factors discussed under the heading 'Risk Factors' in the Company's Annual Information Form dated March 6, 2025, and 'Risks and Uncertainties' in the Company's Quarterly Management's Discussion and Analysis for the period ended June 30, 2025, copies of which are available under the Company's SEDAR+ profile at These factors should be carefully considered and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Real cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and Real assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
